NCT06893016 Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
| NCT ID | NCT06893016 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Guangdong Raynovent Biotech Co., Ltd |
| Condition | Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 640 participants |
| Start Date | 2025-06-15 |
| Primary Completion | 2026-06-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 640 participants in total. It began in 2025-06-15 with a primary completion date of 2026-06-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years. 2. Body mass index ≥ 28 kg/m2 or ≥24kg/m² to \<28 kg/m2 with at least 1 of the following weight-related comorbidities: a) Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, or the use of at least one antihypertensive medication to maintain normal blood pressure;b) Fasting triglycerides (TG) ≥1.70 mmol/L, fasting low-density lipoprotein cholesterol (LDL-C) ≥4.1 mmol/L, fasting high-density lipoprotein cholesterol (HDL-C) \<1.04 mmol/L, or the need for at least one lipid-lowering treatment to maintain normal lipid levels; c) Obstructive sleep apnea syndrome; d) Fatty liver; e) Cardiovascular disease; e) Polycystic ovary syndrome. 3. History of at least 1 self-reported unsuccessful attempt at weight loss by diet and exercise. Exclusion Criteria: 1. Obesity known to be caused by monogenic mutations, other diseases, or medications. 2. Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2. 3. A history of moderate to severe depression at any time in the past or a score of ≥15 on the PHQ-9 questionnaire at screening; a history of bipolar disorder, schizophrenia, or other severe psychiatric disorders. 4. A history of organ transplantation (excluding corneal transplant), or being currently prepared to undergo organ transplantation. 5. Plans to quit smoking during the study period 6. Allergic constitution (allergic to multiple medications or foods), or those known to be allergic to RAY1225, GLP-1 receptor agonists, or GLP-1 related drugs.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06893016 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06893016 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 640 participants.
Is NCT06893016 currently recruiting?
Yes, NCT06893016 is actively recruiting participants. Contact the research team at pkuphiao@163.com for enrollment information.
Where is the NCT06893016 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06893016 clinical trial?
NCT06893016 is sponsored by Guangdong Raynovent Biotech Co., Ltd. The trial plans to enroll 640 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.